Consistently, the upregulation of HuR, along with its cytoplasmic re‐localization, is associated with disease progression and poor prognosis in patients diagnosed with several types of solid tumours, including breast, colon, ovarian, prostate, pancreatic, and oral cancer (Schultz et al., 2020). Here, ELAVL1 is linked to lip and oral cavity carcinoma.